These findings improved the understanding of the epigenetic regulation of Baicalein, showed that Baicalein inhibited the activity of HDAC‐1 and HDAC‐8 without promoting ABC transporter genes expression, and warrant therapeutic potential of Baicalein for CBF‐AML. The gene discussed is CEBPZ; the disease is acute myeloid leukemia.